𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Therapeutic efficacy of L-asparaginase in the treatment of refractory midfacial peripheral T-cell non-hodgkin’s lymphoma

✍ Scribed by Wei-ben Yong; Yun-tao Zhang; Wen Zheng; Yan Wei; Jun Zhu

Publisher
Chinese Anti-Cancer Association
Year
2000
Tongue
English
Weight
233 KB
Volume
12
Category
Article
ISSN
1000-9604

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase II trial of peg-L-asparaginase i
A phase II trial of peg-L-asparaginase in the treatment of non-hodgkins lymphoma
✍ Hyman B. Muss; Nancy Spell; Diane Scudiery; Robert L. Capizzi; M. Robert Cooper; 📂 Article 📅 1990 🏛 Springer US 🌐 English ⚖ 388 KB

A polyethylene glycol conjugate of L-asparaginase (PEGLA) was administered to 21 patients with refractory non-Hodgkin's lymphoma. The dose given was 2,000 mu/m2 intramuscularly every 2 weeks. Eligibility required at least one prior trial of chemotherapy and ambulatory performance status. At entry, a

Inducible lymphokine-activated killer (L
Inducible lymphokine-activated killer (LAK) cell activity in the peripheral blood of patients with relapsed/refractory non-Hodgkin's lymphoma (NHL)
✍ Kenneth W. Zamkoff; Nora P. Watman; David B. Duggan; Bernard J. Poiesz; Arlan J. 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 453 KB

Therapy with recombinant interleukin-2 (rIL-2) induces clinical response in a significant number of patients with refractory malignant disease. Very few patients with non-Hodgkin's lymphoma (NHL) have been treated with rIL-2. The present study sought to determine if peripheral blood mononuclear cell